Literature DB >> 21773699

Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth.

Hui Xu1, Yan-Long Liu, Yan-Mei Yang, Xin-Shu Dong.   

Abstract

PURPOSE: Increasing experimental evidences suggest that ubiquitin-specific protease 22 (USP22), a cancer stem cell marker, plays a crucial role in pathological processes of epithelial malignancies and other solid tumors, which makes it a potential target for cancer therapy. The aim of this study was to study the roles of USP22 in human colorectal cancer cell line HCT116 by suppressing USP22 expression with micro-interfering RNA (miRNA).
METHODS: With the knock-down of USP22, the changes of cellular proliferation, cell cycle, cell apoptosis, and major vault protein (MVP) expression were investigated. Furthermore, a tumor xenograft model in nude mice was injected with USP22 miRNA silencing vector and the immunohistochemical staining was performed to evaluate the USP22 expression in the tumor.
RESULTS: The knock-down of USP22 protein expression by miRNA resulted in the inhibition of cellular proliferation, the accumulation of cells in the G1 phase, the reduction of apoptosis, and the down-regulation of MVP expression. Furthermore, with orthotopic mice as a model, tumor growth was suppressed when USP22 miRNA silencing vector was injected. Immunohistochemical analyses of tumor sections revealed that USP22 expression in animals decreased when USP22 expression was inhibited by miRNA.
CONCLUSION: These results support the hypothesis that USP22 plays a crucial role in tumor formation and growth by regulating cell proliferation with USP22-dependent signaling pathway. Furthermore, USP22 acts as a major transcriptional factor to regulate MVP drug resistant gene. Taken together, targeting USP22 may offer additional possibilities in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21773699     DOI: 10.1007/s00384-011-1275-8

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  22 in total

1.  The polycomb protein Ring1B generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity.

Authors:  Ronen Ben-Saadon; Daphna Zaaroor; Tamar Ziv; Aaron Ciechanover
Journal:  Mol Cell       Date:  2006-12-08       Impact factor: 17.970

2.  A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing.

Authors:  Yue Zhao; Guillaume Lang; Saya Ito; Jacques Bonnet; Eric Metzger; Shun Sawatsubashi; Eriko Suzuki; Xavier Le Guezennec; Hendrik G Stunnenberg; Aleksey Krasnov; Sofia G Georgieva; Roland Schüle; Ken-Ichi Takeyama; Shigeaki Kato; László Tora; Didier Devys
Journal:  Mol Cell       Date:  2008-01-18       Impact factor: 17.970

3.  Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.

Authors:  Gennadi V Glinsky; Olga Berezovska; Anna B Glinskii
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

4.  Stem cell-ness: a "magic marker" for cancer.

Authors:  John P Lahad; Gordon B Mills; Kevin R Coombes
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

5.  Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells.

Authors:  M Kitazono; T Sumizawa; Y Takebayashi; Z S Chen; T Furukawa; S Nagayama; A Tani; S Takao; T Aikou; S Akiyama
Journal:  J Natl Cancer Inst       Date:  1999-10-06       Impact factor: 13.506

Review 6.  Conjugation and deconjugation of ubiquitin regulating the destiny of proteins.

Authors:  Kwang-Hyun Baek
Journal:  Exp Mol Med       Date:  2003-02-28       Impact factor: 8.718

7.  The drug resistance-related protein LRP is the human major vault protein.

Authors:  G L Scheffer; P L Wijngaard; M J Flens; M A Izquierdo; M L Slovak; H M Pinedo; C J Meijer; H C Clevers; R J Scheper
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

8.  Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines.

Authors:  M A Izquierdo; R H Shoemaker; M J Flens; G L Scheffer; L Wu; T R Prather; R J Scheper
Journal:  Int J Cancer       Date:  1996-01-17       Impact factor: 7.396

9.  Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.

Authors:  M A Izquierdo; A G van der Zee; J B Vermorken; P van der Valk; J A Beliën; G Giaccone; G L Scheffer; M J Flens; H M Pinedo; P Kenemans
Journal:  J Natl Cancer Inst       Date:  1995-08-16       Impact factor: 13.506

10.  Membrane transport proteins associated with drug resistance expressed in human melanoma.

Authors:  D Schadendorf; A Makki; C Stahr; A van Dyck; R Wanner; G L Scheffer; M J Flens; R Scheper; B M Henz
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

View more
  13 in total

1.  ShRNA-mediated silencing of the ubiquitin-specific protease 22 gene restrained cell progression and affected the Akt pathway in nasopharyngeal carcinoma.

Authors:  Ya-Jing Zhuang; Zhi-Wei Liao; Hong-Wei Yu; Xian-Lu Song; Yuan Liu; Xing-Yuan Shi; Xiao-Dan Lin; Tong-Chong Zhou
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics.

Authors:  Jun Liang; Xianli Zhang; Shao Xie; Xiuping Zhou; Qiong Shi; Jinxia Hu; Weifeng Wang; Weifeng Qi; Rutong Yu
Journal:  Med Oncol       Date:  2014-02-27       Impact factor: 3.064

Review 3.  Pro-apoptotic and anti-apoptotic regulation mediated by deubiquitinating enzymes.

Authors:  Hae-Seul Choi; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2022-02-03       Impact factor: 9.261

4.  The relationship between the expression of USP22, BMI1, and EZH2 in hepatocellular carcinoma and their impacts on prognosis.

Authors:  Run Zhai; Fang Tang; Jianhua Gong; Jing Zhang; Biao Lei; Bo Li; Yangchao Wei; Xingsi Liang; Bo Tang; Songqing He
Journal:  Onco Targets Ther       Date:  2016-11-24       Impact factor: 4.147

5.  USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma.

Authors:  Songlin Piao; Yanlong Liu; Jing Hu; Fulin Guo; Jie Ma; Yao Sun; Bin Zhang
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

6.  RNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest.

Authors:  Zhao Hui Li; Yin Yu; Chao DU; Hong Fu; Jian Wang; Yu Tian
Journal:  Oncol Lett       Date:  2013-02-12       Impact factor: 2.967

7.  Ubiquitin-specific peptidase 22, a histone deubiquitinating enzyme, is a novel poor prognostic factor for salivary adenoid cystic carcinoma.

Authors:  Wei Dai; Yuan Yao; Qing Zhou; Chang-fu Sun
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

8.  Targeting ubiquitin-specific protease 22 suppresses growth and metastasis of anaplastic thyroid carcinoma.

Authors:  Hua-Dong Zhao; Hai-Li Tang; Ning-Ning Liu; Ya-Li Zhao; Qin-Qin Liu; Xiao-Shan Zhu; Lin-Tao Jia; Chun-Fang Gao; An-Gang Yang; Jun-Tang Li
Journal:  Oncotarget       Date:  2016-05-24

Review 9.  Ubiquitin Specific Peptidase 22 Regulates Histone H2B Mono-Ubiquitination and Exhibits Both Oncogenic and Tumor Suppressor Roles in Cancer.

Authors:  Lucile M-P Jeusset; Kirk J McManus
Journal:  Cancers (Basel)       Date:  2017-12-06       Impact factor: 6.639

10.  Prognostic and clinicopathological significance of ubiquitin-specific protease 22 overexpression in cancers: evidence from a meta-analysis.

Authors:  Ning Ao; Liang Wang; Yuqin Liu
Journal:  Onco Targets Ther       Date:  2017-11-21       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.